Table 4. Medications used by the participants.

Variables	FMS group		CLBP group		Healthy control group		p
	n	%	n	%	n	%
Drug using before pandemic							<0.001**
Amitriptyline	12	2.6‡	1	0.2	0	0.0
Food supplement	5	1.1†	12	2.7	34	7.7‡
Duloxetine	206	44.9‡	33	7.5†	2	0.5†
Gabapentin	10	2.2	17	3.9‡	0	0.0†
Muscle relaxants	42	9.2	81	18.4‡	4	0.9†
Muscle relaxants topical	3	0.7	12	2.74	0	0.0
Not using	34	7.4†	126	28.6†	385	87.5‡
NSAID oral	34	7.4	96	21.8‡	2	0.5
NSAID topical	0	0.0	17	3.9‡	1	0.2
Paracetamol	10	2.2	19	4.3	11	2.5
Pregabalin	63	13.7‡	20	4.5	0	0.0†
Pregabalin-Duloxetine	15	3.3‡	0	0.0	0	0.0
SSRI	25	5.4‡	4	0.9	1	0.2†
Tramadol	0	0.0	3	0.7	0	0.0
Drug using after pandemic							<0.001**
Amitriptyline	14	3.0	7	1.6	0	0.0
Food supplement	9	2.0†	20	4.5	35	8.0‡
Duloxetine	209	45.4‡	25	5.7†	2	0.5†
Gabapentin	12	2.6	12	2.7	0	0.0†
Muscle relaxants	40	8.7	64	14.5‡	5	1.1†
Muscle relaxants topical	3	0.7	14	3.2‡	1	0.2
Not using	29	6.3†	130	29.5†	380	86.4‡
NSAID oral	33	7.2	92	20.9‡	3	0.7†
NSAID topical	2	0.4	19	4.3‡	0	0.0
Paracetamol	13	2.8	24	5.4	11	2.5
Pregabalin	63	13.7‡	28	6.3	0	0.0†
Pregabalin-Duloxetine	11	2.4‡	0	0.0	0	0.0
SSRI	22	4.8‡	3	0.7	2	0.5
Tramadol	0	0.0	3	0.7	1	0.2
FMS: Fibromyalgia syndrome; CLBP: Chronic low back pain; NSAID: Nonsteroidal anti-inflammatory drug; SSRI: Selective serotonin reuptake inhibitors; * Pearson chi-squared test; ** Fisher Freeman-Halton test; Percentages with ‡ and † indicate higher and lower values than expected values considering the independence, respectively.